Ciloxan

Yersinia pestis, Urinary tract infection, acute otitis externa caused by Staphylococcus aureus + 56 more

Treatment

50 FDA approvals

7 Active Studies for Ciloxan

What is Ciloxan

Ciprofloxacin

The Generic name of this drug

Treatment Summary

Ciprofloxacin is an antibiotic that belongs to a class of drugs called fluoroquinolones. It is used to treat various bacterial infections and can be taken orally, intravenously, in the ear, eye, or nose. It was first approved by the FDA in 1987 and is available in many different forms.

Cipro

is the brand name

image of different drug pills on a surface

Ciloxan Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Cipro

Ciprofloxacin

1987

590

Approved as Treatment by the FDA

Ciprofloxacin, also known as Cipro, is approved by the FDA for 50 uses such as Communicable Diseases and Febrile Neutropenia .

Communicable Diseases

Febrile Neutropenia

Used to treat Febrile Neutropenia in combination with Piperacillin

Cystitis

Urinary Tract Infections

Sinusitis

Urinary tract infection

Osteomyelitis

Urinary Tract Infections

Urinary tract infection

Cystitis

Urinary tract infection

Bone and Joint Infections

Lower respiratory tract infection caused by Escherichia coli

Escherichia urinary tract infection

UTI caused by Citrobacter diversus

UTI caused by Providencia rettgeri

Lower respiratory tract infection caused by penicillin-susceptible Streptococcus pneumoniae

prostatitis

UTI caused by Citrobacter frendii

uncomplicated Gonorrhea caused by Neisseria gonorrhoeae

Lower respiratory tract infection caused by Haemophilus parainfluenzae

Acute Sinusitis

UTI caused by methicillin-susceptible Staphylococcus epidermidis

inhaled anthrax caused by Bacillus anthracis

Salmonella typhi

Proteus mirabilis

Proteus mirabilis

Escherichia coli

Infectious diarrhea

Escherichia coli

Klebsiella pneumoniae

Moraxella catarrhalis

Helps manage Acute Exacerbations of Chronic Bronchitis caused by Moraxella catarrhalis

UTI caused by Entercococcus faecalis

Serratia marcescens

acute, uncomplicated Cystitis caused by Staphylococcus saprophyticus

Complicated Intra-Abdominal Infections (cIAIs)

Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole

Skin Infections

UTI caused by Morganella morganii

acute, uncomplicated Cystitis caused by Escherichia coli

complicated Pyelonephritis caused by Escherichia coli

Febrile Neutropenia

Used to treat Febrile Neutropenia in combination with Piperacillin

Gonorrhea

Escherichia coli

Urinary Tract Infections

Haemophilus influenzae

Pseudomonas aeruginosa

Urinary tract infection

Abdominal Infection

Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole

Lower respiratory tract infection caused by Enterobacter cloacae

Klebsiella pneumoniae

Effectiveness

How Ciloxan Affects Patients

Ciprofloxacin is an antibiotic that works against both common and uncommon bacteria. It does this by blocking two enzymes that bacteria need to survive, called DNA gyrase and topoisomerase IV. Ciprofloxacin is a hundred times more effective at blocking these enzymes in bacteria compared to in humans. Additionally, it has no cross resistance with other types of antibiotics, making it a useful tool when other antibiotics are no longer effective. This drug is also being looked into as a possible treatment for malaria, cancer, and AIDS.

How Ciloxan works in the body

Ciprofloxacin works by preventing bacteria from replicating their DNA. It does this by blocking the enzymes that help the bacteria to twist and coil its DNA. By stopping this process, Ciprofloxacin stops the bacteria from reproducing.

When to interrupt dosage

The proposed dose of Ciloxan is contingent upon the diagnosed condition, including Proteus mirabilis, Conjunctivitis and Cystitis. The dosage varies, in accordance to the implementation approach (e.g. Kit; Powder, for suspension - Oral or Kit; Suspension) featured in the table beneath.

Condition

Dosage

Administration

Urinary Tract Infections

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Urinary tract infection

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Moraxella catarrhalis

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

acute otitis externa caused by Staphylococcus aureus

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

inhaled anthrax caused by Bacillus anthracis

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Serratia marcescens

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Proteus mirabilis

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Cystitis

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Klebsiella pneumoniae

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Cystitis

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Gonorrhea

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Escherichia coli

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Lower respiratory tract infection caused by Escherichia coli

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Infectious diarrhea

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Plague

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Corneal Ulcer

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Corneal Ulcer

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Urinary tract infection

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Otitis Externa

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Escherichia coli

, 2.0 mg/mL, 10.0 mg/mL, 500.0 mg, 3.0 mg/mL, 425.2 mg, 250.0 mg, 287.5 mg, 750.0 mg, 3.5 mg/mL, 40.0 mg/mL, 5.0 mg/mL, 574.9 mg, 212.6 mg, 1000.0 mg, 0.3 %, 100.0 mg, 6.0 mg/mL, 20.0 mg/mL, 0.003 mg/mg, 0.2 %, 60.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 3.5 mg, 500.1 mg, 1000.1 mg, 4.0 mg/mL, 500.0 mg/mL, 6.0 mg/mg, 400.0 mg, 250.0 mg/mL, 200.0 mg, 7.5 mg/mL

, Suspension - Auricular (otic), Auricular (otic), Suspension, Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, solution, Injection, solution - Intravenous, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Injection - Intravenous, Injection, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution, Solution - Ophthalmic, Solution / drops - Auricular (otic), Topical, Solution / drops - Topical, Tablet, coated - Oral, Tablet, coated, Tablet, extended release - Oral, Tablet, extended release, Solution - Intravenous, Liquid, Liquid - Intravenous, Intratympanic, Suspension - Intratympanic, Suspension / drops, Suspension / drops - Auricular (otic), Solution, concentrate - Intravenous, Solution, concentrate, Kit, Suspension - Oral, Solution - Auricular (otic), Ointment, Kit - Oral, Tablet, multilayer, extended release - Oral, Tablet, multilayer, extended release, Suspension - Auricular (otic); Intratympanic, Auricular (otic); Intratympanic, Ointment - Ophthalmic

Warnings

Ciloxan has six contraindications, and should not be taken when one is experiencing any of the conditions in the following table.

Ciloxan Contraindications

Condition

Risk Level

Notes

External auditory canal structure

Do Not Combine

Fungal ear infection

Do Not Combine

Pulse Frequency

Do Not Combine

Tympanic Membrane Perforation

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Ciprofloxacin may interact with Pulse Frequency

There are 20 known major drug interactions with Ciloxan.

Common Ciloxan Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Ciprofloxacin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Ciprofloxacin.

Acetaminophen

Major

The metabolism of Acetaminophen can be decreased when combined with Ciprofloxacin.

Acyclovir

Major

The metabolism of Acyclovir can be decreased when combined with Ciprofloxacin.

Agomelatine

Major

The serum concentration of Agomelatine can be increased when it is combined with Ciprofloxacin.

Ciloxan Toxicity & Overdose Risk

An overdose of ciprofloxacin may cause nausea, vomiting, abdominal pain, crystals in the urine, reduced kidney function, and decreased urine output. This could progress over the next 6 days with rising levels of creatinine and urea in the blood. Patients may need prednisone, dialysis, or other supportive treatments. Depending on the severity of the overdose, patients may either recover normal kidney function or have chronic kidney failure. The lowest toxic dose of ciprofloxacin in rats is greater than 2000mg/kg. The drug has low absorption and is generally not a risk during pregnancy or breastfeeding

image of a doctor in a lab doing drug, clinical research

Ciloxan Novel Uses: Which Conditions Have a Clinical Trial Featuring Ciloxan?

No active trials are presently assessing the potential of Ciloxan to treat Pseudomonas aeruginosa, Escherichia coli and Cystitis.

Condition

Clinical Trials

Trial Phases

Febrile Neutropenia

3 Actively Recruiting

Phase 2, Not Applicable

Otitis

3 Actively Recruiting

Not Applicable

Tympanostomy tube insertion

0 Actively Recruiting

Escherichia coli

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Yersinia pestis

0 Actively Recruiting

Cystitis

0 Actively Recruiting

Otitis

0 Actively Recruiting

Pseudomonas aeruginosa

0 Actively Recruiting

Gonorrhea

0 Actively Recruiting

inhaled anthrax caused by Bacillus anthracis

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Plague

0 Actively Recruiting

Corneal Ulcer

0 Actively Recruiting

acute otitis externa caused by Staphylococcus aureus

0 Actively Recruiting

UTI caused by methicillin-susceptible Staphylococcus epidermidis

0 Actively Recruiting

Lower respiratory tract infection caused by Enterobacter cloacae

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

Ciloxan Reviews: What are patients saying about Ciloxan?

5

Patient Review

7/9/2009

Ciloxan for Ulcer of the Cornea of the Eye with Bacterial Infection

My daughter's eye swelling went down significantly after just three applications.

4.3

Patient Review

6/22/2011

Ciloxan for Pink Eye from Bacterial Infection

This treatment has been good for the redness and irritation of my eyelids. However, my eyelids are swollen and have white particles in the tissue of lower lids.

3.7

Patient Review

1/12/2009

Ciloxan for Pink Eye from Bacterial Infection

This medication was helpful when my infant scratched my eye--but I had to use numbing drops before applying this, which kind of defeats the purpose. All in all, though, it did its job without any nasty side effects.

3

Patient Review

9/26/2009

Ciloxan for Pink Eye from Bacterial Infection

I experienced a lot of irritation, burning, and itching around my eye area.

2

Patient Review

3/18/2009

Ciloxan for Pink Eye from Bacterial Infection

The only downside to this treatment is the inconvenience of using an ointment rather than drops. So far, no negative side effects otherwise.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ciloxan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Ciloxan eye drops?

"CILOXAN can be used to treat corneal ulcers and superficial infections of the eye and adnexa that are caused by certain strains of bacteria. Keep in mind any official guidance that exists on the appropriate use of antibacterial agents."

Answered by AI

Are Ciloxan and ciprofloxacin the same?

"The active ingredient in Ciloxan Eye Drops is ciprofloxacin hydrochloride, which is a type of antibiotic known as a fluoroquinolone. This antibiotic is effective against bacteria that cause infections. A prescription from a doctor is required to obtain Ciloxan Eye Drops."

Answered by AI

How long does Ciloxan take to work?

"You should generally feel better within a few days after taking ciprofloxacin, but this depends on the type of infection. If you don't start feeling better after a couple of days, or if you feel worse at any point, be sure to tell your doctor."

Answered by AI

What is Ciloxan used to treat?

"It will not work for other types of eye infections (e.g., viruses, fungi).

This text is discussing the usage of the medication ciprofloxacin to treat eye infections caused by bacteria. The medication belongs to a class of drugs known as quinolone antibiotics. These drugs work by stopping the growth of bacteria. It's important to note that this medication will only work on bacterial eye infections, and not on infections caused by viruses or fungi."

Answered by AI

Clinical Trials for Ciloxan

Image of Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center in Cleveland, United States.

Alio Smart Patch Monitoring for Cancer Patients

18 - 65
All Sexes
Cleveland, OH

Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study, participants will wear an Alio Smartpatch™. The Alio Smartpatch™ is a wireless remote monitoring system. This device will measure participants' vital signs and blood levels. Participants will also be asked to use continuous glucose monitors to measure their glucose levels. The data collected on each participant from these devices will be remotely monitored at all times by clinical staff at a company known as Quantify Remote Care. If a participant's results look like they are experiencing a side effect, the participant will be contacted immediately by Quantify Remote Care team. The Quantify Remote Care team will function as an extension of the participant's cancer clinical team and will relay any significant issues back to them. Quantify Health also provides dietary and mental health support as needed for all participants.

Recruiting
Has No Placebo

Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center

Alberto Montero, MD, MBA

Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA

The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.

Recruiting
Has No Placebo

Ronald Reagan UCLA Medical Center

Image of Denver Health and Hospital Authority in Denver, United States.

Interventions for Ear Infections

6 - 17
All Sexes
Denver, CO

This study aims to improve care and reduce unnecessary antibiotic prescribing for children with ear infections. The study will compare the effectiveness of a "gold standard" to a hybrid intervention combined with this gold standard, in order to identify steps to increase parent satisfaction for child ear infection care. The "gold standard" approach is a Health System Level Intervention. On its own, it involves clinician education, tools in electronic medical records, and audit and feedback reports for clinician prescribing habits. The hybrid intervention includes the elements of the health systems level intervention in addition to a Shared Decision-Making component, which allows for both an increase in the role parents play in their child's care, as well as clinician education for how to use this method. The goals of this work are to increase parent satisfaction, reduce antibiotics taken for childhood ear infections, align medical care with the current national guidelines, and evaluate differences in the two intervention groups. Both groups will be evaluated for implementation outcomes to improve dissemination and scalability for future use of these models in antibiotic prescribing for children with ear infections. This study will recruit a diverse group of patients and clinicians to complete surveys, parents to participate in focus groups, and clinicians and administrators to be interviewed in order to meet study aims and receive sufficient feedback on the interventions performed. There are two hypotheses for this research: 1. The Hybrid Intervention will have higher parent satisfaction and reduced antibiotic use compared to the Health-System Level Intervention and 2. The Hybrid Intervention will be more challenging to implement than the Health-System Level Intervention, but will be preferred by parents, clinicians, and administrators.

Recruiting
Has No Placebo

Denver Health and Hospital Authority (+2 Sites)

Holly Frost, MD

Have you considered Ciloxan clinical trials?

We made a collection of clinical trials featuring Ciloxan, we think they might fit your search criteria.
Go to Trials
Image of Denver Health and Hospital Authority in Denver, United States.

Shorter Antibiotic Courses for Ear Infections

2 - 17
All Sexes
Denver, CO

The overarching goal of this study is to evaluate the effectiveness and implementation outcomes of two low-cost interventions of different intensities to increase prescribing of recommended short antibiotic durations for acute otitis media (AOM) for children 2 years of age and older. A multi-center cluster randomized controlled trial using a hybrid type 2 implementation effectiveness design will be used to evaluate interventions. The High-Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields, whereas the Low-Intensity intervention will include clinician education and EHR changes. In total, 46 community-based clinics and/or urgent care centers across two distinct geographic regions in the United States will be randomized to one of the two interventions. The Practical Robust Implementation and Sustainability Model (PRISM) will be used to guide implementation and the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework will be used to evaluate outcomes. A mixed-methods approach will be used in the pre-implementation and evaluation phases and will utilize quantitative analyses, semi-structured interviews, focus groups, surveys, and cost analyses. National stakeholders at the American Academy of Pediatrics and the Centers for Disease Control and Prevention will assist with dissemination of findings and scaling of interventions.

Waitlist Available
Has No Placebo

Denver Health and Hospital Authority

Timothy C Jenkins, MD